BioNow Annual Awards 2013 Winners –

Two spin out companies that Medipex Ltd set up were among the Winners of this years prestigious BioNow Annual Awards, one the major event of the UK Biomedical sector showcasing the very best of this world class sector. The winners were announced on the evening of the Awards Dinner which took place on Thursday 28th November 2013 at the Mere Golf Resort & Spa, Cheshire and which was attended by over 330 executives from across the biomedical industry. The two winning technologies included:

• ELAROS of Medical Devices Technologies International (MDTi)ELAROS was selected as the INNOVATIVE AGEING AWARD OF THE YEAR. The technology is a simple and effective method to assess patients with continence problems from the comfort of their own home.  A simple hand held PDA is used in conjunction with secure compliant software, that enables patient data to be recorded, analysed and stored as part of the electronic patient record held by the GP or continence nurse based within the surgery. A decision can then be made quickly whether to adopt conservative treatment administered locally or whether the symptoms warrant a referral in to the Urologist, usually in the local hospital. A simple analysis of the data supports clinical diagnosis and allows comparison on effectiveness of treatment over time.
For full press release, please see this article.

• Zilico LtdZEDSCAN was selected as the BEST PRODUCT OF THE YEAR – This innovative technology is a quicker, more reliable method for cancer diagnosis. The technology is an Electrical Impedance Spectroscopy (EIS) system which exploits the different electrical resistivity of normal, pre-cancerous and cancerous tissue. The first product – Zedscan I is for the diagnosis of cervical cancer and having recently been passed as safe and received CE certification is now being launched. This ground-breaking system offers quicker and more accurate detection of cervical neoplasia in real-time, enabling clinicians to improve patient management. ZedScan I offers clinical benefits by identifying the optimum biopsy site and so reducing the number of cervical biopsies required whilst also facilitating a wider use of 'select & treat'. As well as its clinical benefits, a recent independent health economic report has demonstrated that ZedScan I delivers cost-effective benefits to healthcare systems.
For full press release, please see this article.


Sign up to our e-newsletter for all the latest news and updates from Medipex.

*All fields are required